Hodgkin lymphoma – history and current approach

Czech version

Authors: Čepelová Michaela
Authors‘ workplace: Klinika dětské hematologie a onkologie, 2. lékařská fakulta Univerzity Karlovy a Fakultní nemocnice v Motole, Praha
Published in: Čes-slov Pediat 2022; 77 (5): 272-275.
Category: Comprehensive Report
doi: https://doi.org/10.55095/CSPediatrie2022/043

Overview

Hodgkin lymphoma is systemic lymphoproliferative disorder diagnosed mainly in older children and adolescents, which accounts for about 10% of all lymphomas. Over the past century, Hodgkin lymphoma has transformed from a fatal disease to one of the most curable cancers with estimated 5 year survival rates exceeding 95%. Current treatment strategies are aimed at identifying the optimal balance between maintaining overall survival and avoidance of the late effects of treatment with significant decrease in quality of life.

Keywords:

Hodgkin lymphoma – Chemotherapy – radiotherapy – targeted therapy

Sources

1. Kanzler H, Küppers R, Hansmann ML, et al. Hodgkin’s and Reed–Sternberg cells in Hodgkin’s disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996; 184: 1495–505.

2. Bräuninger A, Schmitz R, Bechtel D, et al. Molecular biology of Hodgkin’s and Reed/Sternberg cells in Hodgkin’s lymphoma. Int J Cancer 2006; 118(8): 1853–61. doi: 10.1002/ijc.21716.

3. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102(12): 3871–9. doi: 10.1182/blood-2003-06-1841.

4. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin’s disease. Haematologica 2001; 86(3): 266–73. PMID: 11255273.

5. Bangerter M, Moog F, Buchmann I, et al. Whole-body 2-[18F]-fluoro- -2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease. Ann Oncol 1998; 9(10): 1117–22. doi: 10.1023/a:1008486928190.

6. Pusey WA. Cases of sarcoma and Hodgkin’s disease treated by exposure to X-rays: preliminary report. J Am Med Assoc 1902; 38: 166–169.

7. Engert A, Schiller P, Josting A, et al. German Hodgkin’s Lymphoma Study Group. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2003; 21(19): 3601–8. doi: 10.1200/JCO.2003.03.023.

8. Devita Jr VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 1970; 73: 881– 895. doi: 10.7326/0003-4819-73-6-881.

9. Bonadonna G, Valagussa P, Santoro A, et al. Hodgkin’s disease: the Milan Cancer Instituteexperience with MOPP and ABVD. Recent Res Cancer Res. 1989; 117: 169–74. doi: 10.1007/978-3-642-83781-4_17.

10. Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 20(3): 630–7. doi: 10.1200/ JCO.2002.20.3.630.

11. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009; 27(27): 4548–54. doi: 10.1200/JCO.2008.19.8820.

12. Mauz-Körholz C, Landman-Parker J, Balwierz W, et al. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol 2022; 23(1): 125–137. doi: 10.1016/S1470- 2045(21)00470-8.

13. Daw S, Hasenclever D, Mascarin M, et al. Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group. Hemasphere 2020; 4(1): e329. doi: 10.1097/HS9.0000000000000329.

14. Shankar A, Hall GW, Gorde-Grosjean S, et al. Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin‘s lymphoma – an Anglo-French collaborative report. Eur J Cancer 2012; 48(11): 1700–6. doi: 10.1016/j.ejca.2011.10.018.